Sanavia Oncology Inc.
Silvana Di Giandomenico is the Vice President of Research at Sanavia Oncology Inc. since February 2022. Prior experience includes roles as a Research Associate and Postdoctoral Researcher at Weill Cornell Medicine from June 2013 to January 2022, and as a PhD student at Istituto Mario Negri from September 2009 to November 2012, focusing on the molecular mechanisms of Trabectedin in Myxoid liposarcoma. Silvana began a career in research as a research technician at Memorial Sloan-Kettering Cancer Center from September 2007 to September 2009. Educational qualifications include a Doctor of Philosophy (PhD) in Molecular Pharmacology from The Open University (2009-2012) and a degree in Molecular Biology from the University of Milan (2001-2007).
This person is not in any teams
This person is not in any offices
Sanavia Oncology Inc.
We are a New York-based biotech company with a team of drug developers from Memorial Sloan-Kettering Cancer Center, Rockefeller University, Weill Cornell Medicine and Columbia University. Majority of cancer patients do not benefit from currently available therapies due to drug resistance. We are developing novel immunotherapies that can safely and effectively overcome that drug resistance and improve patients' lives. We use our proprietary platform to discover clinically relevant, cancer-specific epitopes in different types of drug resistant tumors and to generate antibodies with atomic-level specificity to these epitopes. We combine high throughput sequencing, single-molecule super-resolution microscopy, 3D protein modeling and artificial intelligence with novel in vivo models for validating our targets and developing next generation immunotherapies that can safely and effectively eliminate drug-resistant tumors.